226 results on '"hormone-resistant prostate cancer"'
Search Results
2. Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
3. Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
4. Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (PROMOTE)
5. Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
6. Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
7. Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
8. Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
9. Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
10. Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
11. Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
12. Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
13. Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer
14. Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
15. Feasibility of a New Technology for Isolating Circulating Tumour Cells (CTC-SMMiL-E)
16. Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
17. Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
18. Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
19. Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
20. Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
21. Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
22. Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
23. Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
24. Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
25. Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO (XOFIGO)
26. Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
27. Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
28. Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
29. Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
30. Tivantinib in Treating Patients With Metastatic Prostate Cancer
31. Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (DEXTER)
32. Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
33. AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
34. Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
35. Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
36. Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
37. Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
38. Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
39. Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
40. NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
41. Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
42. Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer
43. Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
44. Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
45. Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
46. Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
47. Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer
48. Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
49. Saracatinib in Treating Patients With Prostate Cancer
50. Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.